Cantor Fitzgerald Keeps Their Buy Rating on Zoetis

By Carrie Williams

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Zoetis (NYSE: ZTS), with a price target of $98. The company’s shares closed yesterday at $83.02, close to its 52-week high of $86.38.

Chen noted:

“We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98.”

According to, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.3% and a 40.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Zoetis has an analyst consensus of Moderate Buy, with a price target consensus of $91.71.

See today’s analyst top recommended stocks >>

Based on Zoetis’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.37 billion and net profit of $352 million. In comparison, last year the company earned revenue of $1.23 billion and had a net profit of $238 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services.These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.The firm provides its services though five categories namely, anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceuticals. The company was founded in July 2012 and is headquartered in New York, NY.